智通财经APP获悉，可穿戴心脏设备制造商Kestra Medical Technologies(KMTS.US)以每股17美元的价格发行1190万股股票，高于14 - 16美元的发行价区间，筹资2.02亿美元。该公司发行的股票比预期多190万股。Kestra于3月6日(周四)登陆纳斯达克，上市首日收涨28.47%。
Kestra正在商业化其心脏康复系统平台，这是一个综合且先进的系统，将监测、治疗、数字健康和患者支持服务整合为一个统一的解决方案。该平台的基石是ASSURE WCD，这是一种下一代可穿戴心脏复律除颤器(WCD)，用于保护心脏骤停风险较高的患者。截至2025年1月31日，Kestra的系统已被美国550多家医院(约占全国WCD处方医院的20%)积极采用，自2022年8月全面商业化以来，已有超过1.7万名患者使用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.